Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

BNTX vs REGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REGN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

REGN Overall Winner 6-Pillar Tally: BNTX 1 – 5 REGN Matrix Metrics: BNTX 4 – 6 REGN

As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over BioNTech SE American Depositary Share (BNTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BNTX carries a Unified Composite Score of 43.3/100 (HOLD) at $81.38 (7.0x Forward P/E, -55.5% operating margin), whereas REGN carries 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin).

  • Composite vs. Pillar Nuance: While BNTX currently prints a higher short-term Unified Composite Score (43.3/100 HOLD vs. REGN 42.6/100 HOLD), REGN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (30.4% vs. -55.5% operating margin) and revenue trajectory (+36.3% vs. -15.1% YoY).
  • Technical & Structure Timing Caution: BNTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7); meanwhile REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BNTX vs REGN
BNTX NASDAQ
BioNTech SE American Depositary Share
Biological Products, (No Diagnostic Substances)
$81.38
-2.26% 1D
Market Cap $20.6B
TTM Revenue $2.42B
Forward P/E 7.0x
Beta / 30D Vol 0.81β · 31% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 22.0 Fund 45.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $86.68 · SMA50: $91.83
REGN NASDAQ Head-to-Head Winner
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$923.34
-2.35% 1D
Market Cap $97.8B
TTM Revenue $16.9B
Forward P/E 14.9x
Beta / 30D Vol 0.32β · 55% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 19.0 Fund 45.0 Flow 68.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.5% over 20 days), RSI 58
RSI-14: 57.9 · SMA20: $907.12 · SMA50: $826.97

6-Pillar Scorecard Institutional Category Breakdown (BNTX 1 – 5 REGN)

Columns: Metric · BNTX · REGN
1. Valuation Multiples BNTX
Forward P/E 7.0x 14.9x
Trailing P/E 7.0x 20.9x
PEG Ratio 0.05x 1.15x
EV / Revenue 8.5x 5.7x
2. Growth & Scale REGN
Revenue Growth (YoY) -15.1% +36.3%
Earnings Growth (YoY) -43.2% +35.5%
TTM Revenue (USD) $2.42B $16.9B
Market Cap $20.6B $97.8B
3. Profitability & Quality REGN
Gross Margin 76.7% 46.7%
Operating Margin -55.5% 30.4%
Net Profit Margin -60.9% 28.5%
Return on Equity (ROE) -8.1% 14.9%
4. Balance Sheet & Cash Flow REGN
Cash Generation (TTM) -$1.02B EBITDA $3.63B
Cash Flow Margin -42.0% EBITDA Mgn 21.5%
Net Cash / Leverage $80.26 Book/Sh · -8.1% ROE $952M Net Cash
Dividend Yield None (0.00%) 0.39%
5. Options & Positioning REGN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 41.9% (76th %ile) 35.5% (6th %ile)
Put/Call OI Skew Thin ADR Chain 0.47x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat REGN
OpEx & R&D Intensity N/A 16.3% of Rev ($2.75B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BNTX (4) vs REGN (6)
Institutional Metric BNTX REGN Criterion Row Edge
Market Capitalization
Scale
$20.6B $97.8B Larger Scale REGN
Trailing P/E Ratio
Valuation
7.0x 20.9x Lower Multiple BNTX
Forward P/E Ratio
Valuation
7.0x 14.9x Lower Multiple BNTX
Revenue Growth (YoY)
Growth
-15.1% +36.3% Higher Growth REGN
Operating Margin (TTM)
Profitability
-55.5% 30.4% Higher Margin REGN
Net Profit Margin
Profitability
-60.9% 28.5% Higher Margin REGN
Return on Equity (ROE)
Capital Efficiency
-8.1% 14.9% Higher ROE REGN
52-Week Range Position
Momentum
4% ($80–$124) 83% ($592–$992) Stronger Trend REGN
Beta / 30D Volatility
Risk Regime
0.81β · 31% Vol 0.32β · 55% Vol Lower Realized Risk BNTX
Unified Institutional Score
Composite Signal
43.3 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite BNTX
Trailing 12M Revenue (USD)
Operating Scale
$2.42B $16.9B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
76.7% 46.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.05x PEG · 8.5x EV/Rev 1.15x PEG · 5.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.02B EBITDA ($80.26 Book/Sh · -8.1% ROE) $3.63B ($952M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REGN +25.47 pp
BNTX: -10.86% · REGN: +14.61%
3M Horizon REGN +40.9 pp
BNTX: -30.19% · REGN: +10.71%
6M Horizon REGN +54.19 pp
BNTX: -10.5% · REGN: +43.69%
1Y Horizon REGN +47.93 pp
BNTX: -20.63% · REGN: +27.3%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BNTX vs REGN. Trailing 12-month operating profitability (BNTX -55.5% vs REGN 30.4%) and valuation multiples (BNTX 7.0x vs REGN 14.9x Forward P/E) are benchmarked directly in Pillar 4 below.

BNTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.42B
Gross Margin76.7%
Op. Margin-55.5%
ROE / Fwd P/E-8.1% · 7.0x
REGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$16.9B
Gross Margin46.7%
Op. Margin30.4%
ROE / Fwd P/E14.9% · 14.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BNTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 41.9%
IV Percentile 76th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BNTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
REGN CONSOLIDATION
55d in phase · OBV ACCUMULATION
Current IV 35.5%
IV Percentile 6th %ile
Put/Call OI Skew 0.47x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact REGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $952.40 · IV 33.5%

REGN Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($95,240)

Compare $95,240 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 33.5% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $950 / $1,000 Bull Call Spread

Buy 1x $950C · Sell 1x $1,000C · 31d

Net Entry $2,387 Debit
T+5d @ +5% Move +$891 (+37%)
Max Risk / Buffer $2,387 Capped
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $880 / $820 Bull Put Spread

Sell 1x $880P · Buy 1x $820P · 59d

Net Entry $1,367 Credit
Max Credit / Yield +$1,367 (+29.5% RoM)
Max Risk / Buffer -9.0% Cushion ($4,633 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $880P / $960-$1,040C Seagull

Sell 1x $880P · Buy 1x $960/$1,040C · 31d

Net Entry $1,185 Debit
T+5d @ +5% Move +$2,220 (+15.8% RoM)
Max Risk / Buffer -7.6% Put Cushion ($14,093 Mgn)
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BNTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.6B market capitalization and -55.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
REGN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.8B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment 16.3% of Rev ($2.75B)
90D Engineering Disclosures 0 Published

Investor FAQ BNTX vs REGN Key Questions & Quantitative Answers

As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over BioNTech SE American Depositary Share (BNTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BNTX carries a Unified Composite Score of 43.3/100 (HOLD) at $81.38 (7.0x Forward P/E, -55.5% operating margin), whereas REGN carries 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin). Composite vs. Pillar Nuance: While BNTX currently prints a higher short-term Unified Composite Score (43.3/100 HOLD vs. REGN 42.6/100 HOLD), REGN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (30.4% vs. -55.5% operating margin) and revenue trajectory (+36.3% vs. -15.1% YoY). Technical & Structure Timing Caution: BNTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7); meanwhile REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

REGN leads the Growth & Scale pillar: BNTX posts -15.1% YoY revenue growth and -43.2% YoY earnings growth on $2.42B TTM revenue (76.7% gross margin, -55.5% operating margin), compared with REGN at +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin). On trailing 12-month operating scale, BNTX generates $2.42B in USD-normalized revenue versus $16.9B for REGN. In operating R&D and SG&A reinvestment, BNTX deploys N/A (0 90-day corporate R&D disclosures) versus 16.3% of Rev ($2.75B) (0 disclosures) for REGN.

BNTX screens cheaper on headline valuation multiples. BNTX trades at 7.0x Forward P/E, 7.0x Trailing P/E, 0.05x PEG, and 8.5x EV/Revenue (-42.0% EBITDA margin), whereas REGN trades at 14.9x Forward P/E, 20.9x Trailing P/E, 1.15x PEG, and 5.7x EV/Revenue (21.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BNTX (-8.1% ROE) versus REGN (14.9% ROE) capital efficiency.

In options market volatility and institutional positioning, BNTX carries 41.9% implied volatility (76th %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 31% Vol realized risk). By comparison, REGN carries 35.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.